Febuxostat Tablets (Xiyaoshi) 40?mg Low price wholesale comparison

描述

Febuxostat is a non?purine selective xanthine oxidase inhibitor that reduces uric acid production by inhibiting purine metabolism pathways. This research-grade tablets—marketed as Xiyaoshi, 40?mg strength—are designed for laboratory studies investigating uric acid biosynthesis, enzyme inhibition, oxidative stress, and related metabolic pathways.

Manufactured by Zhejiang Node Pharmaceutical Co., Ltd., the product is approved under China NMPA registration number H20233825 with drug code 86983521000233 and barcode 6974198632913. Each box contains blister-packed tablets, available in both wholesale and retail quantities. Not for clinical, veterinary, or diagnostic use.

Product Specifications

Mechanism & Research Applications

• Selective XO inhibition: Febuxostat binds to xanthine oxidase, preventing conversion of hypoxanthine/xanthine to uric acid.

• Research uses include:

  • Studies on purine metabolism and uric acid synthesis

  • Gout and hyperuricemia models

  • Oxidative stress and ROS-related pathways

  • Xanthine oxidase activity assays

  • Comparative analysis of enzyme inhibitors

Safety & Handling

• Use: Laboratory research only. Not for clinical, diagnostic, or veterinary use.

• Handling: Use proper lab PPE—gloves, goggles, lab coat.

• Storage: Keep sealed below 30?°C; avoid heat, light, and moisture.

• Disposal: Follow local biosafety and chemical waste protocols.

Core Keywords

Febuxostat tablets, Xiyaoshi febuxostat, xanthine oxidase inhibitor, purine metabolism research, uric acid study compound, Zhejiang Node pharmaceutical febuxostat, lab-grade febuxostat, research enzyme inhibitor, NMPA H20233825 febuxostat, wholesale febuxostat tablets

Research Use Disclaimer

This product is intended exclusively for laboratory research. It is not approved for therapeutic, clinical, diagnostic, or veterinary applications. Misuse may pose health or legal risks. Please ensure compliance with institutional safety and regulatory guidelines.